CN101522671A - 5-(1(s)-氨基-2-羟基乙基)-n-[(2,4-二氟苯基)-甲基]-2-[8-甲氧基-2-(三氟甲基)-5-喹啉]-4-唑甲酰胺的顺丁烯二酸盐、甲苯磺酸盐、反丁烯二酸盐和草酸盐盐类，及其制备方法 - Google Patents

5-(1(s)-氨基-2-羟基乙基)-n-[(2,4-二氟苯基)-甲基]-2-[8-甲氧基-2-(三氟甲基)-5-喹啉]-4-唑甲酰胺的顺丁烯二酸盐、甲苯磺酸盐、反丁烯二酸盐和草酸盐盐类，及其制备方法 Download PDF

Info

Publication number
CN101522671A
CN101522671A CNA2007800382818A CN200780038281A CN101522671A CN 101522671 A CN101522671 A CN 101522671A CN A2007800382818 A CNA2007800382818 A CN A2007800382818A CN 200780038281 A CN200780038281 A CN 200780038281A CN 101522671 A CN101522671 A CN 101522671A
Authority
CN
China
Prior art keywords
formula
compound
salt
salt form
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2007800382818A
Other languages
English (en)
Chinese (zh)
Inventor
陈晓明
陈霄
殷姜古
付晓永
D·J·布里希
关若泽
舒和真
S·崔斯卡
唐琪华
V·里欧塔
Z·夏帕妮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38895795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN101522671(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN101522671A publication Critical patent/CN101522671A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CNA2007800382818A 2006-08-14 2007-08-10 5-(1(s)-氨基-2-羟基乙基)-n-[(2,4-二氟苯基)-甲基]-2-[8-甲氧基-2-(三氟甲基)-5-喹啉]-4-唑甲酰胺的顺丁烯二酸盐、甲苯磺酸盐、反丁烯二酸盐和草酸盐盐类，及其制备方法 Pending CN101522671A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83766106P 2006-08-14 2006-08-14
US60/837,661 2006-08-14

Publications (1)

Publication Number Publication Date
CN101522671A true CN101522671A (zh) 2009-09-02

Family

ID=38895795

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800382818A Pending CN101522671A (zh) 2006-08-14 2007-08-10 5-(1(s)-氨基-2-羟基乙基)-n-[(2,4-二氟苯基)-甲基]-2-[8-甲氧基-2-(三氟甲基)-5-喹啉]-4-唑甲酰胺的顺丁烯二酸盐、甲苯磺酸盐、反丁烯二酸盐和草酸盐盐类，及其制备方法

Country Status (11)

Country Link
US (1) US7956189B2 (cg-RX-API-DMAC7.html)
EP (1) EP2069337A1 (cg-RX-API-DMAC7.html)
JP (3) JP2010500406A (cg-RX-API-DMAC7.html)
CN (1) CN101522671A (cg-RX-API-DMAC7.html)
AR (1) AR062373A1 (cg-RX-API-DMAC7.html)
CA (1) CA2660703A1 (cg-RX-API-DMAC7.html)
CL (1) CL2007002366A1 (cg-RX-API-DMAC7.html)
MX (1) MX2009001770A (cg-RX-API-DMAC7.html)
PE (1) PE20080424A1 (cg-RX-API-DMAC7.html)
TW (1) TW200819446A (cg-RX-API-DMAC7.html)
WO (1) WO2008021271A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112714762A (zh) * 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2609659C (en) 2005-05-26 2014-01-28 Neuron Systems, Inc. Azanaphthalenes, compositions and methods for treating retinal disease
CA2782015C (en) 2009-12-11 2020-08-25 Neuron Systems, Inc. Topical ophthalmic compositions and methods for the treatment of macular degeneration
WO2014012859A1 (en) * 2012-07-19 2014-01-23 Boehringer Ingelheim International Gmbh Fumaric acid salt of 9-[4-(3-chloro-2-fluoro-phenylamino)-7-methoxy- chinazolin-6-yloxy]-1,4-diaza-spiro[5.5]undecan-5-one, its use as medicament and the preparation thereof
AU2014209387B2 (en) 2013-01-23 2018-11-01 Aldeyra Therapeutics, Inc. Toxic aldehyde related diseases and treatment
EP4400106A1 (en) 2015-08-21 2024-07-17 Aldeyra Therapeutics, Inc. Deuterated compounds and uses thereof
WO2019075136A1 (en) 2017-10-10 2019-04-18 Aldeyra Therapeutics, Inc. TREATMENT OF INFLAMMATORY DISORDERS
CN113784954A (zh) 2019-05-02 2021-12-10 奥尔德拉医疗公司 多晶型化合物和其用途
US12098132B2 (en) 2019-05-02 2024-09-24 Aldeyra Therapeutics, Inc. Process for preparation of aldehyde scavenger and intermediates
CA3175856A1 (en) 2020-05-13 2021-11-18 Todd Brady Pharmaceutical formulations and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2417993C9 (ru) * 2004-05-18 2011-10-10 Шеринг Корпорейшн Замещенные 2-хинолилоксазолы, пригодные в качестве ингибиторов фдэ4

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112714762A (zh) * 2018-08-06 2021-04-27 奥尔德拉医疗公司 多晶型化合物及其用途

Also Published As

Publication number Publication date
TW200819446A (en) 2008-05-01
WO2008021271A1 (en) 2008-02-21
PE20080424A1 (es) 2008-04-28
US7956189B2 (en) 2011-06-07
AR062373A1 (es) 2008-11-05
JP2012176989A (ja) 2012-09-13
JP2013032394A (ja) 2013-02-14
JP2010500406A (ja) 2010-01-07
CL2007002366A1 (es) 2008-03-14
CA2660703A1 (en) 2008-02-21
MX2009001770A (es) 2009-02-25
US20080108818A1 (en) 2008-05-08
EP2069337A1 (en) 2009-06-17

Similar Documents

Publication Publication Date Title
CN101522671A (zh) 5-(1(s)-氨基-2-羟基乙基)-n-[(2,4-二氟苯基)-甲基]-2-[8-甲氧基-2-(三氟甲基)-5-喹啉]-4-唑甲酰胺的顺丁烯二酸盐、甲苯磺酸盐、反丁烯二酸盐和草酸盐盐类，及其制备方法
US8927771B2 (en) Pharmaceutically acceptable cocrystals of N-[2-(7-methoxyl-1-naphtyl)ethyl]acetamide and methods of their preparation
CN103958469B (zh) 一种新的普利多匹定盐酸盐多晶型形态
US7956048B2 (en) Polymorphs of eltrombopag and eltrombopag salts and processes for preparation thereof
KR20180030964A (ko) 이브루티닙과 카복실산의 공결정체
JP6554617B2 (ja) １−（５−（２，４−ジフルオロフェニル）−１−（（３−フルオロフェニル）スルホニル）−４−メトキシ−１ｈ−ピロール−３−イル）−ｎ−メチルメタンアミン塩の新規な結晶形
CA2743426A1 (en) New crystal form of sunitinib malate
JP2011513349A (ja) Ｎ−［２−（ジエチルアミノ）エチル］−５−［（５−フルオロ−１，２−ジヒドロ−２−オキソ−３ｈ−インドール−３−イリデン）メチル］−２，４−ジメチル−１ｈ−ピロール−３−カルボキサミドの結晶形およびその製造方法
WO2014008794A1 (zh) 一种酪氨酸激酶抑制剂的二马来酸盐的i型结晶及制备方法
JP2024099797A (ja) ７－シクロペンチル－２－（５－ピペラジン－１－イル－ピリジン－２－イルアミノ）－７Ｈ－ピロロ［２，３－ｄ］ピリミジン－６－カルボン酸ジメチルアミドのコハク酸塩の新規な結晶形態
CN115433246A (zh) 葡萄糖胺衍生物的晶型、制备方法及用途
JP6816036B2 (ja) ヒストン脱アセチル化阻害剤の結晶形態
KR20250003750A (ko) [2-(1h-인돌-3-일)-1h-이미다졸-4-일](3,4,5-트리메톡시페닐)메타논 및 이의 염의 다형체
JP2018522928A (ja) Ｆｇｆｒ阻害剤の合成方法
JP7472024B2 (ja) ファソラセタムの固体形態
JP7152122B2 (ja) エダラボン塩
JP2022508791A (ja) ジヒドロピリジン系カルシウム拮抗薬共結晶、その製造方法及び使用
JP2022508864A (ja) チロシンキナーゼ阻害剤のマレイン酸塩の結晶形及びその調製方法
CN107698563B (zh) 制备马来酸来那替尼晶型的方法
TW202334098A (zh) 吡嗪類衍生物的鹽的晶型及其製備方法
EP1768969B1 (en) Crystalline mycophenolate sodium
WO2012044189A1 (en) A new hydrated crystalline form of perindopril erbumine, methods for its preparation and its use in pharmaceutical preparations
WO2013181384A1 (en) Solid state forms of aleglitazar sodium
TW201636346A (zh) 二－匹多莫德苄乙二胺及其固體型
JP2019529465A (ja) キナゾリン誘導体の塩、その製造方法および使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20090902